APTO

Aptose Biosciences (APTO)

Aptose Biosciences Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:APTO

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/11/27	08:56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/26	06:27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/26	06:15	GlobeNewswire Inc.	Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/25	20:05	Edgar (US Regulatory)	Form 424B4 - Prospectus [Rule 424(b)(4)]	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/22	22:05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/22	22:00	GlobeNewswire Inc.	Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/22	14:15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/20	22:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/20	21:30	GlobeNewswire Inc.	Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/15	05:22	Edgar (US Regulatory)	Form SC 13G - Statement of Beneficial Ownership by Certain Investors	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/09	06:02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/11/09	06:01	GlobeNewswire Inc.	Aptose Reports Results for the Third Quarter 2024	NASDAQ:APTO	Aptose Biosciences Inc
2024/10/31	19:39	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:APTO	Aptose Biosciences Inc
2024/10/05	05:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/09/07	05:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/09/06	05:20	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/09/06	05:15	GlobeNewswire Inc.	Aptose Announces Results from Special Meeting of Shareholders	NASDAQ:APTO	Aptose Biosciences Inc
2024/08/31	05:35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/08/31	05:30	GlobeNewswire Inc.	Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib	NASDAQ:APTO	Aptose Biosciences Inc
2024/08/16	05:35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/08/16	05:30	GlobeNewswire Inc.	Aptose Announces Adjournment of its Special Meeting of Shareholders	NASDAQ:APTO	Aptose Biosciences Inc
2024/08/09	06:22	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:APTO	Aptose Biosciences Inc
2024/08/09	06:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/08/09	06:06	GlobeNewswire Inc.	Aptose Reports Results for the Second Quarter 2024	NASDAQ:APTO	Aptose Biosciences Inc
2024/07/27	05:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/07/20	06:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/07/20	06:00	GlobeNewswire Inc.	Aptose Announces Receipt of Deficiency Notice from Nasdaq	NASDAQ:APTO	Aptose Biosciences Inc
2024/07/18	00:43	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:APTO	Aptose Biosciences Inc
2024/06/14	20:40	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc
2024/06/04	05:35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:APTO	Aptose Biosciences Inc